The new H1 antihistamines. Treatment of urticaria and other clinical problems.
The new H1 antihistamines are a major therapeutic advancement in the treatment of allergic disorders such as urticaria and allergic rhinitis. Their efficacy combined with greatly reduced sedating and anticholinergic side effects makes the new class of H1 antihistamines the first-line treatment in the management of urticaria and mild angioedema. The choice of a particular low-sedating H1 antihistamine depends on pharmacokinetic considerations, the severity of the problem (systemic steroids and epinephrine are the first-line treatment for severe angioedema), and the requirement for limiting the frequency of administration. The efficacy of the new H1 antihistamines in the treatment of itch due to atopic eczema and systemic disease remains uncertain, and further controlled clinical trials are needed to elucidate their possible role in these conditions.
Goldsmith
P
P
Department of Dermatology, University College and Middlesex School of Medicine, Middlesex Hospital, London, United Kingdom.
Dowd
P M
PM
D016589:Astemizole / Q000494:pharmacology / Q000627:therapeutic use; D017332:Cetirizine / Q000494:pharmacology / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000494:pharmacology / Q000627:therapeutic use; D016593:Terfenadine / Q000494:pharmacology / Q000627:therapeutic use; D014311:Triprolidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014581:Urticaria / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D014311:Triprolidine; D017336:Loratadine; D016593:Terfenadine; D016589:Astemizole; C043648:acrivastine; D017332:Cetirizine